Showing results (191-200 of 218) with videos related to
Sort By:
Pageof 22
Annals of the Rheumatic Diseases|October 8, 2021
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19Alessia Alunno, Aurélie Najm, Pedro M Machado, et al.The Lancet. Rheumatology|January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.Arthritis Research & Therapy|January 12, 2005
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopeniaFrederique Ponchel, Robert J Verburg, Sarah J Bingham, et al.Medical Sciences (Basel, Switzerland)|February 9, 2021
COVID-19 Management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases Centre: A Retrospective AnalysisKenneth F Baker, Aidan T Hanrath, Ina Schim van der Loeff, et al.Annals of the Rheumatic Diseases|February 24, 2022
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 updateRobert B M Landewé, Féline P B Kroon, Alessia Alunno, et al.Nature Reviews. Rheumatology|July 14, 2017
Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.Annals of the Rheumatic Diseases|November 7, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementPeter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.Nature Reviews. Rheumatology|September 23, 2017
Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.Nature Reviews. Rheumatology|December 20, 2017
Corrigendum: Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.Trials|July 17, 2019
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocolMariam Al-Laith, Marianna Jasenecova, Sonya Abraham, et al.Pageof 22